Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (2564)	7/29/1999 10:53:00 PM
From: BDR	Read Replies (3) \| Respond to of 10293

A little dilution at a discount, warrants at a premium (raising $25 million). Anyone make anything of this? EntreMed, Inc. Completes Private Placement to Support Clinical Development of Angiogenesis Inhibitors newspage.com "In the private placement, the Company issued shares of common stock and two series of warrants. The Company issued shares of common stock at a 7.5% discount to a five-day averaged market price. The two series of warrants have an exercise price at a significant premium to the present market price and may be called by the Company if the market price for the common stock reaches certain levels." This follows the registration on 7/7/99 of 953,751 shares for sale by, I gather, mostly insiders. freeedgar.com

To: BDR who wrote (2564)	7/30/1999 11:19:00 PM
From: BDR	Read Replies (1) \| Respond to of 10293

Hollis-Eden Pharmaceuticals Appoints Chief Operating Officer/ Chief Financial Officer newspage.com SAN DIEGO, July 29 /PRNewswire/ via NewsEdge Corporation -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH) announced today the appointment of Daniel D. Burgess as Chief Operating Officer and Chief Financial Officer. Mr. Burgess is joining Hollis-Eden from Nanogen Inc., where he served as Vice President and Chief Financial Officer...